Search - tctmd.com

Displaying 1 - 20 of 36

Sort: Relevancy | Date

News Daily News

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

L.A. McKeown

February 06, 2026

News Daily News

Lower-Calorie Mediterranean Diet Plus Exercise Boosts Diabetes Prevention

Todd Neale

August 25, 2025

News Daily News

Healthcare Expenses Increase After GLP-1 Prescription

L.A. McKeown

August 18, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

Todd Neale

July 24, 2025

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

Michael O'Riordan

May 13, 2025

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Daily News

Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key

Todd Neale

November 13, 2024

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

News Daily News

Who Benefits Most From Semaglutide and How Long Will That Take?

Shelley Wood

December 19, 2023

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Shelley Wood

May 30, 2023

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

L.A. McKeown

October 05, 2022

News Conference News EAS 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Michael O'Riordan

May 26, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

Advertisement

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

Lower-Calorie Mediterranean Diet Plus Exercise Boosts Diabetes Prevention

Healthcare Expenses Increase After GLP-1 Prescription

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Who Benefits Most From Semaglutide and How Long Will That Take?

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Dapagliflozin Boosts Health Status Across LVEF Range

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content